<DOC>
	<DOCNO>NCT02581761</DOCNO>
	<brief_summary>A randomized prospective double blind study misoprostol administration asymptomatic patient pregnancy unknown location .</brief_summary>
	<brief_title>A Prospective Study Misoprostol Administration Asymptomatic Patients With Pregnancies Unknown Location</brief_title>
	<detailed_description>A randomized prospective double blind study misoprostol administration asymptomatic patient pregnancy unknown location . The management asymptomatic patient pregnancy unknown location ( PUL ) remain challenge . Determining location pregnancy first priority evaluation woman . Some asymptomatic woman present inappropriate raise beta-human chorionic gonadotropin ( βHCG ) , others assurance pregnancy duration ( e.g . IVF pregnancy ) sonographic evidence intra extra uterine pregnancy . Most PULs fail intra-uterine pregnancy . The main concern regard PUL late diagnosis ectopic pregnancy ( EP ) . Some study report 5 42 % woman see US assessment positive pregnancy test PUL 6-20 % subsequently diagnose EP ( 1 ) . Other study report 94 % PUL resolve spontaneously , 6 % spontaneously resolve 68.9 % finally diagnose fail IUP 5.6 % diagnose EP ( 2 ) . Women PUL evaluate minimum time , also minimal invasiveness . Management resolve pregnancy rapid manner save time money possibly avoid unnecessary administration MTX surgical intervention . Several protocol investigate order fasten diagnosis PUL . For example , obtain serial β-HCG , first one initial presentation , two day later seven day later ( 3 ) . Another protocol suggest endometrial sampling D &amp; C aspiration uterine continent Karman cannula check β-HCG 24 hour ( 2 ) . Purpose : The aim study prospectively assess use misoprostol asymptomatic patient pregnancy unknown location ( PUL ) . The study group contain hemodynamically stable woman &gt; 18 year old PUL abnormal plateauing serum β-HCG trend ( increase &lt; 53 % decrease &lt; 15 % 2 day ) &lt; 1000 IU/l pelvic ultrasound unremarkable intrauterine pregnancy ( IUP ) ectopic pregnancy ( EP ) . Each participant get Vaginal misoprostol 800 mcg placebo . Main Outcome Measure ( ) : The primary outcome measure uneventful decline serum β-HCG undetectable level ( &lt; 2 IU/l ) initial intervention strategy . Secondary outcome measure include additional treatment ( e.g . methotrexate ( MTX ) administration laparoscopy ) , side effect serum β-HCG clearance time , feature optimal candidate treatment cytotec .</detailed_description>
	<mesh_term>Misoprostol</mesh_term>
	<criteria>hemodynamically stable woman &gt; 18 year old PUL abnormal plateauing serum βHCG trend Hemoglobin &lt; 10</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Hemodynamically stable woman &gt; 18 year old</keyword>
	<keyword>abnormal plateauing serum βHCG</keyword>
</DOC>